ARSD

Last update 08 May 2025

Basic Info

Synonyms

ARSD, arylsulfatase D, ASD

Introduction-

100 Clinical Results associated with ARSD

100 Translational Medicine associated with ARSD

0 Patents (Medical) associated with ARSD

371

Literatures (Medical) associated with ARSD

01 May 2025·Journal of Bioscience and Bioengineering

Multi-gene metabolic engineering of Pichia pastoris to synthesize ectoine

Article

Author: Wu, Shuyan ; Mi, Mengjiao ; Liao, Qing ; Cheng, Bingjie ; Huang, Xuewu ; Wang, Xiaoyuang ; Wu, Yue ; Hu, Xiaoqing ; Zhang, Shuai ; Huang, Ming

As a promising osmolyte, ectoine has been widely applied in cosmetics, food, and pharmaceutical industries in recent years, therefore its biomanufacturer has attracted increasing interest. Ectoine-producing isolates were previously screened from halophilic microorganisms. After ectoine synthetase was identified, genetic engineering of Escherichia coli, Corynebacterium glutamicum, and Hansenula polymorpha were employed to produce ectoine. However, Pichia pastoris, another successful host capable of high-density cell culture, had not yet been exploited as an ectoine-synthesizing host. In this study, therefore, P. pastoris was employed for the first time to produce ectoine through multi-gene metabolic engineering. Firstly, Chromohalobacter salexigens HZS/E, a halophilic isolate producing 46.96 mg/mL ectoine, was identified, while ectABC encoding ectoine synthetase was cloned. Later, ectABC was introduced into P. pastoris GS115 under the control of two different promoters. The results showed that P_GAP-based HZS02 accumulated 8.03 g/L, 12.62 % higher than 7.13 g/L produced by P_AOX-based HZS01. Finally, to enhance the supply of the precursor l-aspartate-β-semialdehyde, three genes (aspC, aK, and asD) were individually and collectively overexpressed. The highest ectoine yield was achieved at 10.88 g/L by GS115/pGAPZ A-ectABC-aspC-aK-asD. This study demonstrated that P. pastoris was a highly effective host for ectoine biosynthesis.

01 Apr 2025·Journal of Dairy Science

Milk-derived antimicrobial peptide GMp7: Disrupting protein networks for multi-target antibacterial inhibition and enhanced dairy preservation

Article

Author: Xu, Yujuan ; Yang, Xue ; He, Jinze ; Li, Hong ; Li, Yufang ; Yu, Yuanshan ; Yu, Xiaoyan ; Huang, Aixiang ; Yang, Tingting ; Shi, Yanan

Our goal was to identify and characterize a novel milk-derived antimicrobial peptide, GMp7, and reveal its antibacterial mechanism against Staphylococcus aureus. Therefore, this study revealed the multi-target antibacterial mechanism of GMp7 on S. aureus DC.RB-015 by Fourier-transform infrared spectroscopy, flow cytometry, scanning electron microscopy, and label-free proteomics analysis. The results showed that GMp7 has a secondary structure consisting of 17.45% α-helix, 20.10% β-corner, and 37.13% β-fold, which is conducive to membrane disruption and bacterial cell death. Treatment with GMp7 induced a significant change in the proteome, resulting in the downregulation of 99 proteins and the upregulation of 26 proteins, indicating a multi-target effect on bacterial physiology. Notably, GMp7 forms stable bonds with the critical proteins asd and pcrA within the S. aureus protein network, which includes a larger network of 17 proteins essential for bacterial viability. The binding energies for GMp7 with asd and pcrA were determined to be -8.477 and -8.407 kcal/mol, respectively. GMp7 exerts its bacteriostatic effects through multiple pathways, including interference with peptidoglycan biosynthesis, ATP-binding cassette transport, the 2-component system, DNA replication, and mismatch repair. The efficacy of the peptide against S. aureus in pasteurized milk suggests its potential use in the dairy industry to improve product shelf life and safety. In addition, GMp7 significantly inhibited the growth of S. aureus in milk. These findings have practical significance for the use of antimicrobial peptides to control bacterial contamination in food and improve food safety.

01 Feb 2025·International Immunopharmacology

The combined immunization of cervical cancer therapeutic vaccine based on Listeria balanced lethal system has a significant therapeutic effect on tumor model mice

Article

Author: Zhang, Yunwen ; Wang, Chuan ; Tang, Jing ; Chen, Zhaobin ; Gan, Shanping ; Ou, Qian

Cervical cancer is the fourth most common cancer and the fourth leading cause of cancer death in women. Effective treatment of cervical cancer is urgently needed. Tumor therapeutic vaccine is a research hotspot in tumor immunotherapy, and the tumor therapeutic vaccine based on attenuated live bacteria carrier has clinical application prospect because of its clear action site and high safety. The bacterial balanced lethal system uses nutritional screening instead of antibiotic screening to avoid the risk of the spread of antibiotic resistance. So it is generally recognized as a green carrier. In our early research, we have constructed two cervical cancer therapeutic vaccine candidates (LM-HPVCW-1 and LI-HPVCW-1) based on Listeria balanced lethal system via transforming the nutrient-deficient strains with nutrition gene complementary plasmid. The complementary plasmid contained the nutrition complementary gene, LM dal gene, and its Amp gene was replaced with asd gene to delete the antibiotic resistance. Besides, it carried the shuffled HPV-16 E6E7 fusion protein gene. In vitro experiments showed that the plasmid carried by the candidate strain could be stably passaged and the target protein could be successfully expressed. In this study, we proved that the two candidate strains were safe in vivo and induced cellular immune response. At the same time, by establishing a tumor-bearing mouse model, it was proved that the two vaccine strains combined immunization could effectively inhibit mouse tumors. The mechanism of tumor suppression may be related to breaking the immunosuppression of tumor microenvironment and inducing CD8⁺ T cell infiltration. The therapeutic vaccine for cervical cancer constructed in this study is expected to be further applied in clinical practice.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

ARSD

Basic Info

Related

Analysis